What are the appropriate injection sites for administering furosemide?

Furosemide Injection Sites

Furosemide is administered intravenously or intramuscularly, NOT subcutaneously with conventional preparations. The FDA-approved routes are IV and IM only 1.

Standard Administration Routes

Intravenous Administration (Primary Route)

Intravenous furosemide is the preferred route for acute heart failure and volume overload because it provides superior bioavailability compared to oral administration 2. The guidelines consistently recommend:

• Initial dosing: 20-40 mg IV bolus for new-onset heart failure or patients not on chronic diuretics 3, 4
• For patients on chronic oral therapy: IV dose should be at least equivalent to the oral dose 3
• Dose range: 40-120 mg IV for acute decompensated heart failure 2

Administration technique for IV furosemide:

• Can be given as intermittent boluses (2-3 times daily) or continuous infusion 2, 5, 3
• Continuous infusion is superior to repeated large-dose boluses and at least as safe 2
• High doses (>6 mg/kg/day in pediatrics) should be infused over 5-30 minutes to avoid ototoxicity 6

Intramuscular Administration

IM administration is FDA-approved 1 but rarely used in clinical practice because:

• IV route provides better bioavailability
• IM injections are painful and less practical for repeated dosing
• No clear advantage over IV route in acute settings

Important Contraindication: Conventional Subcutaneous Administration

Conventional furosemide preparations should NOT be administered subcutaneously due to:

• Significant skin irritation (3-23% of patients) 7
• Skin infections requiring antibiotics (3-17%) 7
• The acidic pH of conventional preparations causes tissue damage

Novel pH-Neutral Subcutaneous Preparations

Recent pH-neutral, concentrated preparations (e.g., Furoscix®) have been developed specifically for subcutaneous use 7, 8:

• Bioavailability of 99.7-112% compared to IV furosemide 7
• Well-tolerated with minimal skin reactions
• These are distinct pharmaceutical formulations, not the standard furosemide injection
• Particularly effective in patients with diuretic resistance 8

Clinical Context for Route Selection

For acute heart failure with congestion:

• Use IV route as first-line 2, 3
• Good oral bioavailability in cirrhotic patients favors oral over IV in stable cirrhosis 9
• Acute reductions in GFR associated with IV furosemide in cirrhosis support oral route when appropriate 9

For chronic management:

• Oral administration is preferred for stable outpatients
• IV furosemide approximately twice as potent as oral 5

Key Safety Considerations

• Monitor closely: Electrolytes, renal function, volume status, and blood pressure 2, 3
• Avoid rapid IV push of high doses: Infuse over 5-30 minutes to prevent ototoxicity 6
• Protect from light and use only if solution is clear 1
• Preservative-free formulations: Discard unused portions 1